PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01037790 |
Recruitment Status :
Recruiting
First Posted : December 23, 2009
Last Update Posted : August 22, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with refractory solid tumors.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Adult Solid Tumor Adenocarcinoma of the Colon Adenocarcinoma of the Rectum Adult Central Nervous System Germ Cell Tumor Adult Teratoma Benign Teratoma Estrogen Receptor-negative Breast Cancer Estrogen Receptor-positive Breast Cancer Familial Testicular Germ Cell Tumor HER2-negative Breast Cancer HER2-positive Breast Cancer Male Breast Cancer Ovarian Immature Teratoma Ovarian Mature Teratoma Ovarian Monodermal and Highly Specialized Teratoma Progesterone Receptor-negative Breast Cancer Progesterone Receptor-positive Breast Cancer Recurrent Breast Cancer Recurrent Colon Cancer Recurrent Extragonadal Germ Cell Tumor Recurrent Extragonadal Non-seminomatous Germ Cell Tumor Recurrent Extragonadal Seminoma Recurrent Malignant Testicular Germ Cell Tumor Recurrent Melanoma Recurrent Ovarian Germ Cell Tumor Recurrent Rectal Cancer Stage III Extragonadal Non-seminomatous Germ Cell Tumor Stage III Extragonadal Seminoma Stage III Malignant Testicular Germ Cell Tumor Stage III Ovarian Germ Cell Tumor Stage IV Breast Cancer Stage IV Colon Cancer Stage IV Extragonadal Non-seminomatous Germ Cell Tumor Stage IV Extragonadal Seminoma Stage IV Melanoma Stage IV Ovarian Germ Cell Tumor Stage IV Rectal Cancer Testicular Immature Teratoma Testicular Mature Teratoma | Drug: PD-0332991 Other: pharmacological study | Phase 2 |
PRIMARY OBJECTIVES:
I. To determine the response rates following treatment with PD 0332991 in the following malignancies: 1) Metastatic breast cancer, 2) Metastatic colorectal cancer, 3) Metastatic melanoma with CDK4 mutation or amplification, or 4) Cisplatin-refractory, unresectable germ cell tumors.
II. To evaluate the safety and tolerability of PD 0332991 administered to subjects with refractory solid tumors.
SECONDARY OBJECTIVES:
I. To assess the pharmacodynamic effects of PD0332991 on tumor and non-tumor tissue.
II. To investigate the relationship between selected biomarkers, PK and/or efficacy and safety outcomes.
III. To estimate the population pharmacokinetic for PD 0332991 and to correlate PK with efficacy outcomes.
IV: To perform a Phase II evaluation of PD 0332991 in a population defined as potential responders on the basis of CCND1 gene amplification.
OUTLINE:
Patients receive oral PD 0332991 once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of unacceptable toxicity or disease progression.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 205 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
Study Start Date : | October 2009 |
Estimated Primary Completion Date : | October 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 1
Metastatic breast cancer
|
Drug: PD-0332991
Given orally, 125 mg QD on a 21-day Other: pharmacological study Correlative study
Other Name: pharmacological studies |
Experimental: Arm 2
Metastatic colorectal cancer that harbors the Kras or BRAF mutation
|
Drug: PD-0332991
Given orally, 125 mg QD on a 21-day Other: pharmacological study Correlative study
Other Name: pharmacological studies |
Experimental: Arm 3
Advanced or metastatic esophageal and/or gastric cancer
|
Drug: PD-0332991
Given orally, 125 mg QD on a 21-day Other: pharmacological study Correlative study
Other Name: pharmacological studies |
Experimental: Arm 4
Cisplatin-refractory, unresectable germ cell tumors
|
Drug: PD-0332991
Given orally, 125 mg QD on a 21-day Other: pharmacological study Correlative study
Other Name: pharmacological studies |
Experimental: Arm 5
Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.
|
Drug: PD-0332991
Given orally, 125 mg QD on a 21-day Other: pharmacological study Correlative study
Other Name: pharmacological studies |
- Response rates [ Time Frame: 5 years ]
- Safety and tolerability [ Time Frame: 5 years ]
- Pharmacodynamic effects on tumor and non-tumor tissue [ Time Frame: 5 years ]
- Relationship between selected biomarkers, pharmacokinetics, and/or efficacy and safety outcomes [ Time Frame: 5 years ]
- Population pharmacokinetic for PD 0332991 and correlation with efficacy outcomes [ Time Frame: 5 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Disease Characteristics:
All Subjects: All subjects treated under this protocol will have histologically documented cancer of one of the following types:
A. Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B. Metastatic colorectal cancer that harbors the Kras or BRAF mutation (15-30 enrollment slots) C. Advanced or metastatic esophageal and/or gastric cancer (15-30 enrollment slots) D. Cisplatin-refractory, unresectable germ cell tumors (15-30 enrollment slots) E. Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification OR any other functional alteration at the G1/S checkpoint. (15-30 enrollment slots)
- Biopsy Requirements: For Subjects with accessible disease amenable to biopsy: A biopsy will be obtained pre-treatment and in during cycle 1 (while patient is receiving drug) for molecular markers of the cell cycle, and its inhibition.
- Subjects will be > 18 years old
- The subject has disease that is assessable by tumor marker, physical, or radiologic means.
- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- The subject has adequate organ function, defined as follows A. Bilirubin ≤ 1.5 x the upper limit of normal (ULN) B. Serum creatinine ≤ 1.5 x UNL or calculated creatinine clearance ≥ 60 mL/min, and C. For subjects without liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN D. For subjects with liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase ≤ 5 x ULN
- All tumors must test positive for Rb expression except:
A. ER positive metastatic breast tumors (data now shows all to be Rb positive.) B. Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification OR any other functional alteration at the G1/S checkpoint.
- The subject has adequate marrow function, defined as follows: A. Absolute neutrophil count (ANC) >1500/mm3 B. Platelets >100,000/mm3, and C. Hemoglobin > 9 g/dL
- The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document.
- Sexually active subjects (male and female) must use accepted methods of contraception during the course of the study and for 3 months after the last dose of protocol drug(s).
- Female subjects of childbearing potential must have a negative pregnancy test at screening. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months.
- However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, or ovarian suppression.
Exclusion Criteria
- The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within 3 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first dose of PD 0332991. . Patients with HER2-overexpressing tumors may receive trastuzumab up to the date of starting therapy, and may continue to receive trastuzumab while receiving PD0332991.
- The subject has received any other type of investigational agent within 28 days before the first dose of study treatment.
- The subject has not recovered from clinically-meaningful toxicity due to prior therapy (i.e., back to baseline or Grade ≤ 1), with the exception of neurotoxicity and alopecia.
- The subject has untreated or uncontrolled brain metastases or evidence of leptomeningeal involvement of disease unless the subject has a teratoma in which case s/he may be eligible if all other eligibility criteria are met
-
The subject has uncontrolled intercurrent illness including, but not limited to:
- ongoing or active infection
- diabetes mellitus
- hypertension
- symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months
- The subject has a baseline corrected QT interval (QTc) > 470 ms.
- The subject is pregnant or breastfeeding.
- The subject is known to be positive for the human immunodeficiency virus (HIV). Note:
baseline HIV screening is not required
- The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01037790
Contact: Peter O Dwyer, MD | 855-216-0098 | PennCancerTrials@emergingmed.com |
United States, Pennsylvania | |
Abramson Cancer Center of The University of Pennsylvania | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Contact: Peter ODwyer 855-216-0098 PennCancerTrials@emergingmed.com | |
Principal Investigator: Peter ODwyer |
Principal Investigator: | Peter ODwyer | Abramson Cancer Center of the University of Pennsylvania |
Responsible Party: | Abramson Cancer Center of the University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT01037790 History of Changes |
Other Study ID Numbers: |
UPCC 03909 NCI-2009-01467 |
First Posted: | December 23, 2009 Key Record Dates |
Last Update Posted: | August 22, 2018 |
Last Verified: | August 2018 |
Additional relevant MeSH terms:
Breast Neoplasms Neoplasms Melanoma Adenocarcinoma Rectal Neoplasms Colonic Neoplasms Neoplasms, Germ Cell and Embryonal Germinoma Ovarian Neoplasms Teratoma Testicular Neoplasms Breast Neoplasms, Male Seminoma Dermoid Cyst Neoplasms by Site |
Breast Diseases Skin Diseases Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas Carcinoma Neoplasms, Glandular and Epithelial Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases |